Tenax director buys 53,000 shares at $1.92
TENAX THERAPEUTICS, INC.
Rhea-AI Filing Summary
TENAX THERAPEUTICS, INC. (TENX) director Declan Doogan reported a purchase of 53,000 shares of common stock on September 16, 2026 at $1.92 per share in an open-market or private transaction. Following this trade, he directly holds 55,274 common shares.
He also reports direct holdings of several stock options (rights to buy common stock) with exercise prices ranging from $5.75 to $3,200.00 per share and expiration dates between June 10, 2031 and January 9, 2036, covering underlying common shares in multiple option grants.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 53,000 shares
Net Buy
6 txns
Insider
Doogan Declan
Role
Director
Bought
53,000 shs ($102K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 53,000 | $1.92 | $102K |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 55,274 shares (Direct);
Stock Option (right to buy) — 210,008 contracts (Direct)
Key Figures
Common shares purchased: 53,000 shares
Purchase price per share: $1.92 per share
Direct common shares after transaction: 55,274 shares
+4 more
7 metrics
Common shares purchased
53,000 shares
Purchase of TENAX THERAPEUTICS common stock on September 16, 2026
Purchase price per share
$1.92 per share
Open-market or private purchase of TENX common stock on September 16, 2026
Direct common shares after transaction
55,274 shares
Direct holdings of TENAX THERAPEUTICS common stock following the reported purchase
Stock option exercise price
$13.30 per share
One stock option grant expiring January 9, 2036, on 30,000 underlying common shares
Stock option exercise price
$5.75 per share
One stock option grant expiring July 1, 2035, on 80,000 underlying common shares
Stock option exercise price
$5.94 per share
One stock option grant expiring December 10, 2034, on 100,000 underlying common shares
High exercise price option
$3,200.00 per share
Stock option expiring June 10, 2031, on 4 underlying common shares
Key Terms
Stock Option (right to buy), open market or private transaction, underlying common shares, exercise price, +1 more
5 terms
Stock Option (right to buy) financial
"He also reports direct holdings of several stock options (right to buy common stock)"
open market or private transaction financial
"purchase of 53,000 shares of common stock at $1.92 per share in an open-market or private transaction"
exercise price financial
"stock options with exercise prices ranging from $5.75 to $3,200.00 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration dates financial
"exercise prices ranging from $5.75 to $3,200.00 per share and expiration dates between June 10, 2031 and January 9, 2036"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TENAX THERAPEUTICS (TENX) director Declan Doogan report?
Declan Doogan reported a purchase of 53,000 TENX common shares on September 16, 2026 in an open-market or private transaction at $1.92 per share, increasing his reported direct ownership of common stock.
Is the reported TENX insider transaction a buy or sell?
The Form 4 shows a buy transaction: Declan Doogan purchased 53,000 TENAX THERAPEUTICS common shares, with no sales reported in this filing, resulting in a net-buy position for the reported date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
